Skip to content

ELASMOGEN

discovering and developing soloMERs for the treatment of auto-immune mediated, inflammatory diseases

ELASMOGEN
  • about
    • the team
    • the board
    • investors
    • Jobs
  • soloMER technology
    • discovery platform
    • product development options
  • pipeline
    • auto-Immune / anti-Inflammatory
    • oncology
    • NDURE programme
  • partners
    • licensing
    • partnerships and collaborations
  • news
    • press release
    • publications
    • events
  • contact
  • job vacancy
Press release

Press release

  • Home
  • News
  • Press release
  • Press release
  • Publications
  • Events

News archives

  • November 2019
  • July 2019
  • May 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • August 2018
  • May 2018
  • January 2018
  • November 2017
  • May 2017
  • March 2017
  • January 2017
  • July 2016
  • March 2016

Elasmogen featured in CONVERGE podcast | 19.11.2019

Elasmogen’s CEO, Caroline Barelle is featured in Converge’s podcast where she discusses her business journey.

Elasmogen CEO Caroline Barelle featured in news outlets as a leader in biotech space | 05.11.2019

CIOLook, is currently running a special edition on most prominent women leaders and Elasmogen’s CEO, Caroline Barelle has given an interview giving her perspective on leadership in the biotech industry. You can read the profile here. BioBeat has featured Caroline Barelle in their report 50 Movers and Shakers in BioBusiness 2019 which showcases the trailblazers and […]

Caroline Barelle featured in Insights Success | 03.07.2019

Elasmogen’s CEO Dr Caroline Barelle has been featured in Insight Success special edition Successful Women Making a Difference in Biotech. The article can be read here.   Dr. Caroline Barelle: A Leader in Biotechnology Driving Innovation in Biologics Drug Development    

Elasmogen CEO Caroline Barelle named one of top 20 women in leading biotech roles in Europe | 21.05.2019

Biotech media outlet Labiotech.eu which covers the European Biotech industry, has today, 21 May 2019, listed Elasmogen CEO, Dr Caroline Barelle among top 20 women in leading biotech roles in Europe. The full article can be found at https://labiotech.eu/tops/women-leaders-biotech-europe/ -ENDS-

Elasmogen CEO shortlisted for BBSRC Innovator of the Year 2019 award | 01.05.2019

Elasmogen is delighted to announce that shortlisted finalists for the 2019 BBSRC Innovator of the Year award include our CEO, Dr Caroline Barelle. The BBSRC Innovator of the Year award recognises the full breadth of impacts that BBSRC investments in research have on  lives, society and the economy. It celebrates the individuals and small teams who have […]

Almac Discovery and Elasmogen to Share Anti-ROR-1 VNAR Data at American Association of Cancer Annual Meeting | 20.03.2019

Craigavon, N.I., UK, 20 Mar 2019 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Elasmogen a biotech company developing next generation therapeutic biologics, today announced they will present a poster on their VNAR-based protein drug conjugates research targeting ROR1 at the upcoming American Association […]

Elasmogen CEO Caroline Barelle Interviewed by Life Sciences Scotland for Leadership Insight | 30.01.2019

Life Sciences Scotland have interviewed Elasmogen’s CEO Caroline Barelle as part of their Insight series. The article can be accessed here.

Elasmogen Licenses NDure™ Half-life Extension Technology to ImmunoForge | 07.01.2019

Novel soloMER based albumin binder will be used for two therapeutic fusion proteins™ Aberdeen, Scotland and Seoul, Korea; January 7th 2019:  Elasmogen Ltd, developer of next generation soloMER biologics, announced today that ImmunoForge has entered a license agreement to Elasmogen’s proprietary NDure half-life extension technology for use in two non-disclosed targets.  ImmunoForge will be responsible […]

Elasmogen winner of BioFIT 2018 Start-up Slams | 07.12.2018

  Lille, 5 December 2018 – Elasmogen wins another prestigious award during the 7th Edition of BioFIT. BioFIT is one of Europe’s leading business conventions for technology transfer, academia-industry collaborations and early-stage innovations in the field of Life Sciences. It is also becoming an important marketplace for seed investment in Life Sciences by facilitating early-stage financing deals and gives participants an opportunity to access information about current events and trends in […]

Elasmogen CEO Dr Caroline Barelle wins ‘Academic Entrepreneur of the Year’ award at Entrepreneurial Scotland’s Summit Awards 2018 | 26.11.2018

Elasmogen’s CEO Dr Caroline Barelle won the Academic Entrepreneur of the Year award at Entrepreneurial Scotland’s Summit Awards ceremony which took place on 22nd November 2018 in Glasgow. Commenting on her win, Caroline says “I am delighted to be recognised for championing science-led enterprise at a national level. It is a fantastic achievement, and there […]

ELASMOGEN Copyright 2019

Liberty Building | Foresterhill Health Campus | Aberdeen | AB25 2ZP

  • info@elasmogen.com
  • twitter
  • linkedin